Amin Masoud, Vakilian Alireza, Mahmoodi Mohammad Hossein, Hassanshahi Gholamhossein, Falahati-Pour Soudeh Khanamani, Dolatabadi Maryam Rafiei, Nadimi Ali Esmaeili
Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Department of Neurology, Ali-Ebne-Abitaleb Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Eurasian J Med. 2017 Jun;49(2):92-96. doi: 10.5152/eurasianjmed.2017.17022.
Inflammation plays a significant role in the development of ischemic stroke. CXC chemokines play pleiotropic roles in prolonged leukocyte locomotion, astrocyte migration/activation, and neural attachment/sprouting in response to focal stroke. In this study, we aimed to explore the changes in serum levels of three chemokines, C-X-C motif chemokine ligand 1 (CXCL1), C-X-C motif chemokine ligand 9 (CXCL9), and C-X-C motif chemokine ligand 10 (CXCL10), in ischemic stroke patients at the time of admission and before discharge from the hospital ward.
In this study, we recruited 43 unrelated ischemic stroke patients using an easy convenience method or accidental sampling which is a type of non-probability sampling that involves the sample being drawn from that part of the population that is close to hand. We also enrolled 50 genetically unrelated healthy controls showing no history of neurologic, cardiovascular, or inflammatory diseases. Serum levels of the considered chemokines were measured by enzyme-linked immunosorbent assay (ELISA) in patients and healthy controls.
No significant difference was observed in ischemic stroke patients following hospitalization and prior discharging from the hospital; however, there was a significant difference in serum levels of CXCL9 and CXCL10 between patients and healthy controls. We also found that the level of the chemokine was not related to gender or medical therapy. It appears that CXCL9 and CXCL10 are more predisposing factors and play a direct role in stroke considering that they were higher in patients than in healthy controls.
We believe that this study might be used as a basis for further studies on more effective medication regimens to prevent the onset and subsequent complications of stroke. However, these mediators are useful diagnostic and prognostic tools rather than therapeutic tools.
炎症在缺血性脑卒中的发展过程中起重要作用。CXC趋化因子在局灶性脑卒中后白细胞长时间移动、星形胶质细胞迁移/激活以及神经附着/发芽过程中发挥多效性作用。在本研究中，我们旨在探讨缺血性脑卒中患者入院时及出院前血清中三种趋化因子，即C-X-C基序趋化因子配体1（CXCL1）、C-X-C基序趋化因子配体9（CXCL9）和C-X-C基序趋化因子配体10（CXCL10）水平的变化。
在本研究中，我们采用简便的便利抽样方法或偶遇抽样（一种非概率抽样，样本从易于获取的人群中抽取）招募了43例无亲缘关系的缺血性脑卒中患者。我们还纳入了50例无亲缘关系的健康对照者，这些对照者无神经、心血管或炎症性疾病史。通过酶联免疫吸附测定（ELISA）法检测患者和健康对照者血清中上述趋化因子的水平。
缺血性脑卒中患者住院后与出院前未观察到显著差异；然而，患者与健康对照者血清中CXCL9和CXCL10水平存在显著差异。我们还发现趋化因子水平与性别或药物治疗无关。鉴于患者体内CXCL9和CXCL10水平高于健康对照者，似乎它们是更易引发脑卒中的因素，并在脑卒中中起直接作用。
我们认为本研究可为进一步研究更有效的预防脑卒中发病及后续并发症的药物治疗方案提供依据。然而，这些介质是有用的诊断和预后工具，而非治疗工具。
